Jasper Therapeutics (JSPR) AI Stock Analysis

• Market Cap: $41.42M
• Dividend Yield: N/A
• Average Volume (3M): 399.98K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.73
• Revenue Growth: N/A
• EPS Growth: -24.38%
• Country: US
• Employees: 64
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.13
• Shares Outstanding: 27,984,040
• 10 Day Avg. Volume: 455,991
• 30 Day Avg. Volume: 399,984
• PEG Ratio: 0.21
• Price to Book (P/B): 5.06
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.94
• Enterprise Value/Market Cap: -0.23
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 0.10
• 1Y Price Target: $12.00
• Price Target Upside: 669.23% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $2.00 ▲(28.21% Upside)

The score is held back primarily by weak financial performance (no revenue, widening losses, and substantial cash burn with a shrinking equity base), implying continued reliance on external funding. Offsetting this, technicals show improving near-term momentum and corporate updates were constructive with encouraging briquilimab clinical results and clearer path to a Phase 2b CSU study; valuation remains constrained by negative earnings and no dividend support.

Positive Factors

Clinical data & Phase 2b path

Robust Phase 1b/2a and open‑label extension results that enable a defined dose selection materially reduce clinical development design risk. A clear path to a Phase 2b in 2H 2026 increases the probability of efficient late‑stage testing and preserves strategic optionality versus competitors.

Low financial leverage

Minimal debt leaves the company less exposed to interest and covenant constraints, providing structural flexibility to pursue additional financing or partnerships without near‑term default risk. This improves optionality for funding clinical programs versus highly leveraged peers.

Management experience & business development skillset

Promotion of a CEO with deep industry, BD and commercial experience strengthens strategic execution for late‑stage development, partner negotiations, and future commercialization planning. Such seasoned leadership can materially improve fundraising, partnership outcomes, and program prioritization over coming months.

Negative Factors

Heavy cash burn & pre-revenue status

Sustained negative operating and free cash flow while pre‑revenue creates structural funding pressure and ongoing reliance on external financing. Over a 2–6 month horizon this elevates dilution risk, constrains discretionary R&D spending and can force prioritization or delay of development activities if capital markets tighten.

Shrinking equity cushion

A materially reduced equity base weakens the company’s ability to absorb continued operating losses and heightens sensitivity to adverse events. This diminished cushion increases the probability that the firm must seek dilutive financing or restrictive terms, affecting long‑term financial flexibility and strategic options.

Residual clinical execution risk

While the investigation reduces product‑quality concerns, the prior anomalous cohort outcomes highlight ongoing execution and trial design risk. Confirmatory data and proper patient selection are required; lingering uncertainty can delay timelines, complicate regulatory interactions, and increase the chance of additional costly studies.

Jasper Therapeutics Business Overview & Revenue Model

Company Description

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.

How the Company Makes Money

Jasper Therapeutics makes money primarily through the development and commercialization of its proprietary therapies. Revenue streams include potential licensing agreements, partnerships with pharmaceutical companies, and the eventual sales of approved products. The company may also receive funding through research grants and collaboration agreements which support the advancement of its clinical trials. Strategic partnerships with other biotech and pharmaceutical companies contribute significantly to its revenue by providing both financial support and collaborative opportunities to expand its research and development capabilities.

Jasper Therapeutics Financial Statement Overview

Summary

Jasper Therapeutics' financial position is precarious, characterized by a lack of revenue, substantial operating losses, and reliance on external financing. While the balance sheet appears stable for now, continuous cash burn and no revenue generation may challenge future viability. The company must achieve revenue generation to improve financial health and sustainability.

Income Statement

Jasper Therapeutics has consistently reported zero revenue, indicating a lack of commercialized products or services. The company has significant and increasing EBIT and net losses, reflecting high operational costs without offsetting income. This performance suggests severe profitability challenges and raises concerns about long-term sustainability.

Balance Sheet

The company maintains a relatively healthy equity position, with stockholders' equity exceeding total liabilities, resulting in a low debt-to-equity ratio. However, the absence of revenue and ongoing losses are depleting equity, posing risks to future financial stability.

Cash Flow

Jasper Therapeutics reports negative operating and free cash flows, reflecting cash burn without revenue generation. Financing activities, primarily through equity financing, have been necessary to support operations. The lack of cash flow from operations presents a significant risk to liquidity and solvency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-91.89M	-74.87M	-67.75M	-50.22M	-36.46M	0.00
Net Income	-91.02M	-71.27M	-64.47M	-37.69M	-30.64M	-31.67M
Balance Sheet
Total Assets	57.47M	79.90M	94.89M	48.36M	93.65M	23.36M
Cash, Cash Equivalents and Short-Term Investments	50.90M	71.64M	86.89M	38.25M	84.70M	19.84M
Total Debt	1.70M	1.81M	2.79M	3.65M	2.88M	1.62M
Total Liabilities	45.90M	18.23M	16.45M	12.37M	24.14M	58.49M
Stockholders Equity	11.57M	61.67M	78.44M	35.99M	69.52M	-35.13M
Cash Flow
Free Cash Flow	-76.53M	-63.15M	-52.33M	-46.43M	-36.11M	-18.27M
Operating Cash Flow	-76.43M	-62.60M	-52.07M	-45.86M	-33.68M	-18.27M
Investing Cash Flow	-71.00K	-532.00K	-267.00K	-576.00K	-2.43M	0.00
Financing Cash Flow	34.90M	47.88M	100.97M	55.00K	100.97M	11.29M

Jasper Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.56
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JSPR, the sentiment is Negative. The current price of 1.56 is below the 20-day moving average (MA) of 1.77, below the 50-day MA of 1.78, and below the 200-day MA of 3.25, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 40.83 is Neutral, neither overbought nor oversold. The STOCH value of 12.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JSPR.

Jasper Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARTV	58 Neutral	$119.78M	-1.42	-47.96%	―	-100.00%	-17.10%
JSPR	52 Neutral	$41.42M	-0.26	-191.12%	―	―	-24.38%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CBUS	50 Neutral	$103.14M	-0.63	-149.99%	―	-8.64%	85.68%
ACET	46 Neutral	$74.81M	-0.41	-71.73%	―	―	25.89%
BYSI	43 Neutral	$68.26M	―	―	―	―	―
CVM	42 Neutral	$43.14M	-0.66	-176.32%	―	―	48.68%

Jasper Therapeutics Corporate Events

Jasper Therapeutics Reports Strong Briquilimab Data in Urticaria

On January 8, 2026, Jasper Therapeutics reported positive updated clinical results for briquilimab in chronic urticaria, with new Phase 1b/2a BEACON data in adults with CSU and longer-term outcomes from an open-label extension study in CSU and CIndU. In the BEACON trial’s 240mg/180mg Q8W cohort, 83% of briquilimab-treated patients achieved complete response by week 3 and 67% maintained complete response at 12 weeks, with a mean UAS7 reduction of 31 points and no dose-limiting toxicities. The open-label extension showed similarly robust outcomes on a 180mg Q8W regimen, with 58% of CSU patients achieving complete response and 75% achieving at least well-controlled disease at 12 weeks, while 65% of CIndU patients reached complete or partial response by week 16; across 63 patients and a median 205 days of follow-up, KIT-related adverse events were infrequent, low grade and resolved on treatment. The company said the combined efficacy and safety data from these studies are now sufficient to select dosing for a planned Phase 2b study in CSU in the second half of 2026, reinforcing briquilimab’s potential differentiated profile in the competitive chronic urticaria market and signaling a key step toward late-stage development that could be meaningful for patients and investors if confirmed in larger trials.

The most recent analyst rating on (JSPR) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Jasper Therapeutics stock, see the JSPR Stock Forecast page.

Jasper Therapeutics announces leadership transition and briquilimab update

On January 2, 2026, Jasper Therapeutics’ board decided that Chief Executive Officer and President Ron Martell would step down effective January 5, 2026, a termination without cause under his contract that entitles him to 18 months of salary continuation and COBRA coverage, and he simultaneously resigned from the board without any reported disagreements over company matters. Effective January 5, 2026, Chief Operating Officer Jeet Mahal was promoted to Chief Executive Officer and President and joined the board as a Class III director with an increased annual salary of $600,000 and eligibility for a performance bonus of up to 50% of base pay, while Board Chairperson Thomas G. Wiggans was named Executive Chair, formalizing a leadership team aimed at guiding Jasper through its next phase of clinical growth for briquilimab. On January 7, 2026, the company publicly announced these leadership changes and scheduled an investor webinar for January 8, 2026 to present updated data from its BEACON study in CSU and an open-label extension in CSU and CIndU, underscoring a strategic focus on progressing briquilimab toward later-stage development in mast cell–driven diseases.

The most recent analyst rating on (JSPR) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Jasper Therapeutics stock, see the JSPR Stock Forecast page.

Jasper Therapeutics Reports Positive Phase 1b Study Results

On December 2, 2025, Jasper Therapeutics announced positive preliminary clinical data from its ETESIAN Phase 1b study, showing that a single 180mg dose of briquilimab significantly reduced airway hyperresponsiveness and eosinophilic response in adult participants with allergic asthma. The study supports further development of briquilimab as a potential therapeutic option for asthma patients. Additionally, Jasper completed an internal investigation into the lack of clinical response in the July 2025 BEACON study, concluding that the unexpected results were due to patient selection issues rather than problems with the drug product.

The most recent analyst rating on (JSPR) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Jasper Therapeutics stock, see the JSPR Stock Forecast page.